Atrophic Vaginitis Atrophic vaginitis, also called vaginal atrophy, is a condition where the lining of the vagina gets drier and thinner, resulting in itching, burning, and pain during sex, among other symptoms. The condition also includes urinary tract problems such as urinary tract infections (UTIs) and frequent urination. Vaginal refers to the vagina, while atrophy means wasting away or diminution. The term vaginal atrophy has been replaced with the newer term, genitourinary syndrome of menopause (GSM). Atrophic Vaginitis Epidemiology Segmentation in the 7MM <ul><li class="ql-align-justify">Total Prevalent Cases of Atrophic Vaginitis</li><li class="ql-align-justify">Total Diagnosed Cases of Atrophic Vaginitis</li><li class="ql-align-justify">Total Atrophic Vaginitis Cases by Severity</li><li class="ql-align-justify">Total Patients taking Prescription Treatment</li></ul> <a href="https://www.delveinsight.com/report-store/atrophic-vaginitis-epidemiology-forecast" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204); background-color: transparent;">Atrophic Vaginitis Epidemiological Insights</a> Observed in the 7MM (2021) <ul><li class="ql-align-justify">The total incident cases of Atrophic Vaginitis observed in the 7MM were observed to be more than 97 Million in the year 2021</li><li class="ql-align-justify">The total diagnosed Atrophic Vaginitis population accounting for more than 22 Million cases, was found in the United States in the year 2021</li></ul> <a href="https://www.delveinsight.com/report-store/atrophic-vaginitis-market" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204); background-color: transparent;">Atrophic Vaginitis Market Insight</a> The market size of Atrophic Vaginitis in the 7MM was found to be approximately USD 2,777 Million in 2021 including the highest in the US with USD 1,589.1 Million, proceeded by EU5 (USD 796.5 Million) and Japan(USD 391.5 Million).&nbsp; Atrophic Vaginitis Market Strengths Increasing prevalence of atrophic vaginitis, up to 40% of postmenopausal women have symptoms of atrophic vaginitis. Because the condition is attributable to estrogen deficiency, it may occur in pre-menopausal women who take anti-estrogenic medications. Atrophic Vaginitis Market Opportunities The advancements in the technology, as well as diagnostic methodology, would increase the overall patient pool as currently, many patients are underdiagnosed. Atrophic Vaginitis Key Players&nbsp; The key players working in the Atrophic Vaginitis market are <ul><li class="ql-align-justify">Shionogi</li><li class="ql-align-justify">Duchesnay, and others</li></ul>

Atrophic Vaginitis Market

Atrophic Vaginitis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape